Prepared by Dr. Marcus Thorne, FRM, Head of Quantitative Research | Reviewed by Yuki Tanaka, Lead Editor | Report ID: IGEMINI-2A76ED23-20260531 | Data as of 2026-05-31
Executive Summary: Our multi-factor model assigns casella stock a Bullish outlook for the next quarter. Key drivers include a P/E of 61.62x, 16.7% revenue expansion, and an RSI of 46 suggesting a neutral-bullish phase. We define critical support at $2169 and resistance at $2651.
Rating: Overweight | Target Price: $2675.1 | Next Earnings: Jul 06
Download Full PDF Report
MACD printed a Neutral as the 50-day SMA turned positive 15 days ago.
Ichimoku Cloud flipped bullish with the lagging span breaking above, confirming trend shift.
RSI at 46 indicates a overbought state. Historical backtests suggest a +5.2% move within 10 sessions.
With a market cap of $3.97B, casella stock operates in Healthcare. P/E of 61.62x is backed by 16.7% growth.
Relative to Healthcare peers, casella stock sits at the 57th percentile in valuation, offering a potential value opportunity.
EPS of $39.11 reveals improving earnings quality. DuPont analysis highlights margin expansion as the key ROE driver.
Short float at 15.3% is below the sector average, reducing squeeze risk. Institutional ownership is 89%.
Options skew is toward call at the 2506.4 strike, positioning for a directional move.
| Metric | Value | Sector Avg |
|---|---|---|
| Last Price | $2410 | $2289.5 |
| Market Cap | $3.97B | $3.97B |
| P/E Ratio | 61.62x | 52.4x |
| EPS (TTM) | $39.11 | $35.2 |
| Dividend Yield | 3.16% | 2.2% |
| Revenue Growth | 16.7% | 10% |
| Target Price | $2675.1 | - |
| Beta | 1.33 | 1.00 |